Evidence map›Paper›PMID 36678918›Full record

ArticlePharmaceutics2023

Combined Use of Antimicrobial Peptides with Antiseptics against Multidrug-Resistant Bacteria: Pros and Cons.

Maria S Zharkova, Aleksey S Komlev, Tatiana A Filatenkova, Maria S Sukhareva, Elizaveta V Vladimirova, Andrey S Trulioff, Dmitriy S Orlov, Alexander V Dmitriev, Anna G Afinogenova, Anna A Spiridonova and 1 more

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Design and Synthesis of Novel Antimicrobial Agents.Antibiotics (Basel, Switzerland) · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Maria S ZharkovaInstitute of Experimental Medicine, WCRC "Center for Personalized Medicine", 12 Academic Pavlov Street, St. Petersburg 197022, Russia.ORCID 0000-0003-3352-8197
Aleksey S KomlevInstitute of Experimental Medicine, WCRC "Center for Personalized Medicine", 12 Academic Pavlov Street, St. Petersburg 197022, Russia.
Tatiana A FilatenkovaInstitute of Experimental Medicine, WCRC "Center for Personalized Medicine", 12 Academic Pavlov Street, St. Petersburg 197022, Russia.
Maria S SukharevaInstitute of Experimental Medicine, WCRC "Center for Personalized Medicine", 12 Academic Pavlov Street, St. Petersburg 197022, Russia.
Elizaveta V VladimirovaInstitute of Experimental Medicine, WCRC "Center for Personalized Medicine", 12 Academic Pavlov Street, St. Petersburg 197022, Russia.ORCID 0000-0002-6576-9844
Andrey S TrulioffInstitute of Experimental Medicine, WCRC "Center for Personalized Medicine", 12 Academic Pavlov Street, St. Petersburg 197022, Russia.
Dmitriy S OrlovInstitute of Experimental Medicine, WCRC "Center for Personalized Medicine", 12 Academic Pavlov Street, St. Petersburg 197022, Russia.
Alexander V DmitrievInstitute of Experimental Medicine, WCRC "Center for Personalized Medicine", 12 Academic Pavlov Street, St. Petersburg 197022, Russia.
Anna G AfinogenovaSt. Petersburg Pasteur Institute, 14 Mira Street, St. Petersburg 197101, Russia.
Anna A SpiridonovaDepartment of Clinical Microbiology, Pavlov First Saint Petersburg State Medical University, 6/8 Lev Tolstoy Street, St. Petersburg 197022, Russia.
Olga V ShamovaInstitute of Experimental Medicine, WCRC "Center for Personalized Medicine", 12 Academic Pavlov Street, St. Petersburg 197022, Russia.ORCID 0000-0002-5168-2801
Institute of Experimental Medicine · RUFirst Pavlov State Medical University of St. Petersburg · RUSaint Petersburg Pasteur Institute · RUSt Petersburg University · RU

Funding

Ministry of Science and Higher Education of the Russian Federation Agreement № 075-15-2022-302 (20.04.2022), World-Class Research Center "Center for Personalized Medicine".
6 · The paper itself

Abstract

Antimicrobial peptides (AMPs) are acknowledged as a promising template for designing new antimicrobials. At the same time, existing toxicity issues and limitations in their pharmacokinetics make topical application one of the less complicated routes to put AMPs-based therapeutics into actual medical practice. Antiseptics are one of the common components for topical treatment potent against antibiotic-resistant pathogens but often with toxicity limitations of their own. Thus, the interaction of AMPs and antiseptics is an interesting topic that is also less explored than combined action of AMPs and antibiotics. Herein, we analyzed antibacterial, antibiofilm, and cytotoxic activity of combinations of both membranolytic and non-membranolytic AMPs with a number of antiseptic agents. Fractional concentration indices were used as a measure of possible effective concentration reduction achievable due to combined application. Cases of both synergistic and antagonistic interaction with certain antiseptics and surfactants were identified, and trends in the occurrence of these types of interaction were discussed. The data may be of use for AMP-based drug development and suggest that the topic requires further attention for successfully integrating AMPs-based products in the context of complex treatment. AMP/antiseptic combinations show promise for creating topical formulations with improved activity, lowered toxicity, and, presumably, decreased chances of inducing bacterial resistance. However, careful assessment is required to avoid AMP neutralization by certain antiseptic classes in either complex drug design or AMP application alongside other therapeutics/care products.

Indexed as

antibacterial actionantimicrobial peptidesantisepticsbiofilmscombined usedrug-resistant bacteria

Identifiers

PMID36678918
PMCPMC9863607
OpenAlexW4316464202

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.